Results 11 to 20 of about 216,339 (397)

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. [PDF]

, 2014
PurposeWe hypothesized that bortezomib, an agent that suppresses HIF-1α transcriptional activity, when combined with bevacizumab, would obviate the HIF-1α resistance pathway.
Amin, Hesham M, Angelo, Laura S, Falchook, Gerald S, Hess, Kenneth, Hong, David, Howard, Adrienne N, Huang, Mei, Jackson, Edward F, Janku, Filip, Kurzrock, Razelle, Lawhorn, Kristie N, Naing, Aung, Ng, Chaan S, Parkhurst, Kristin L, Tannir, Nizar M, Vishwamitra, Deeksha, Wheler, Jennifer J   +16 more
core   +15 more sources

Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study

Therapeutic Advances in Medical Oncology, 2022
Background: Although bevacizumab in combination with afatinib or erlotinib is an effective and safe first-line therapy for advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), there are very few clinical data ...
Suey-Haur Lee, Yu-Ching Lin, Li-Chung Chiu, Jia-Shiuan Ju, Pi-Hung Tung, Allen Chung-Cheng Huang, Shih-Hong Li, Yueh-Fu Fang, Chih-Hung Chen, Scott Chih-Hsi Kuo, Chin-Chou Wang, Cheng-Ta Yang, Ping-Chih Hsu   +12 more
doaj   +1 more source

Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2023
Importance For patients with RAS wild-type metastatic colorectal cancer, adding anti-epidermal growth factor receptor (anti-EGFR) or anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibodies to first-line doublet chemotherapy is routine ...
J. Watanabe, K. Muro, K. Shitara, K. Yamazaki, M. Shiozawa, H. Ohori, A. Takashima, M. Yokota, A. Makiyama, N. Akazawa, H. Ojima, Y. Yuasa, K. Miwa, H. Yasui, E. Oki, Takeo Sato, Takeshi Naitoh, Y. Komatsu, T. Kato, M. Hihara, J. Soeda, T. Misumi, Kouji Yamamoto, K. Akagi, Atsushi Ochiai, H. Uetake, K. Tsuchihara, T. Yoshino   +27 more
semanticscholar   +1 more source

Toxicity and efficacy of biosimilar bevacizumab in the second-line therapy for metastatic colon cancer in routine clinical practice: results of an independent observational study

Тазовая хирургия и онкология, 2021
Objective: to compare the efficacy and tolerability of second‑line chemotherapy with original bevacizumab (Avastin) and biosimilar bevacizumab produced by “Biocad” (Avegra) in patients with metastatic colon cancer.Materials and methods.
M.   Yu. Fedyanin, F.   V. Moiseenko, M.   A. Lyadova, V.  N.  Vorobyeva, V.  V.  Petkau, A.  V.  Fateeva, E.  S.  Kuzmina, O.  Yu.  Novikova, V.   A. Chubenko, N.  Kh.  Abduloeva, A.  A.  Kudryavtsev, E.   O. Ignatova, R.   R. Shakirov, O.  A.  Pardabekova, L.  V.  Kindyalova, S.  P.  Pelikh, O.   A. Gladkov, S.  A.  Tjulandin, A.  A.  Tryakin   +18 more
doaj   +1 more source

Thyroid dysfunction with atezolizumab plus bevacizumab after lenvatinib in hepatocellular carcinoma: A case series

SAGE Open Medical Case Reports, 2023
Atezolizumab plus bevacizumab is the recommended first-line treatment for unresectable hepatocellular carcinoma, based on guidelines from the Barcelona Clinic Liver Cancer prognosis and treatment strategy.
Takenori Ichimura, Daisuke Ichikura, Miwa Hinata, Noriko Hida, Toshiyuki Baba   +4 more
doaj   +1 more source

Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study

Liver Cancer, 2023
Introduction: Atezolizumab plus bevacizumab therapy is extremely effective in the treatment of intermediate-stage hepatocellular carcinoma (HCC), with a response rate of 44%, as reported in the IMbrave150 trial.
M. Kudo, T. Aoki, K. Ueshima, K. Tsuchiya, M. Morita, H. Chishina, M. Takita, S. Hagiwara, Y. Minami, Hiroshi Ida, N. Nishida, C. Ogawa, Tetsu Tomonari, Noriaki Nakamura, Hidekatsu Kuroda, A. Takebe, Y. Takeyama, M. Hidaka, S. Eguchi, S. Chan, M. Kurosaki, N. Izumi   +21 more
semanticscholar   +1 more source

A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab [PDF]

Journal of Cancer Research and Clinical Oncology, 2021
Abstract Purpose Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor-specific angiogenesis in some cancers. MYL-1402O is a proposed bevacizumab biosimilar. Methods The primary objective of this single-center, randomized,
Matthew Hummel, Tjerk Bosje, Andrew Shaw, Mark Shiyao Liu, Abhijit Barve, Mudgal Kothekar, Mark A. Socinski, Cornelius F. Waller   +7 more
openaire   +4 more sources

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. [PDF]

New England Journal of Medicine, 2014
BackgroundStandard therapy for newly diagnosed glioblastoma is radiotherapy plus temozolomide. In this phase 3 study, we evaluated the effect of the addition of bevacizumab to radiotherapy-temozolomide for the treatment of newly diagnosed glioblastoma ...
O. Chinot, W. Wick, W. Mason, R. Henriksson, F. Saran, R. Nishikawa, A. Carpentier, K. Hoang-Xuan, P. Kavan, D. Cernea, A. Brandes, M. Hilton, L. Abrey, T. Cloughesy   +13 more
semanticscholar   +4 more sources

Ipilimumab and Bevacizumab in Glioblastoma [PDF]

Clinical Oncology, 2016
The median survival in glioblastoma is just over a year, with no standard second-line therapy. Ipilimumab is an immune checkpoint inhibitor that activates the anti-tumour immune response by cytotoxic T-lymphocyte antigen-4 blockade. There is significant evidence supporting its role in the treatment of malignant melanoma, including in patients with ...
Thomas Carter, Denise Cohn-Brown, Kerry A. Chester, Paul Mulholland, Paul Mulholland, Heather Shaw   +5 more
openaire   +5 more sources

Bevacizumab and ovarian cancer [PDF]

Therapeutic Advances in Medical Oncology, 2012
Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that targets vascular endothelial growth factor-A, and is indicated in the treatment of various tumors (colon, lung, renal, and glioblastoma). It has been recently approved for the treatment of ovarian cancer in various countries.
Agustin A. Garcia, Harpreet Singh
openaire   +7 more sources